Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib
In Vivo · 2023
DOI: 10.21873/invivo.13093 ↗Kurz gefasst
Klinische Studie in der Zeitschrift In Vivo, 2023. Verfasst von Alberto Dalla Volta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Br…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Gonads, Kidney Neoplasms, Sunitinib. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Single-agent tyrosine kinase inhibitors are still prescribed as first-line treatment to a relevant subgroup of patients with metastatic renal cell carcinoma (mRCC). These agents are known to cause disfunction of many endocrine glands (e.g., thyroid). In this two-step trial, we aimed to assess gonadal function among male patients with mRCC treated with sunitinib. PATIENTS AND METHODS: We enrolled a first cross-sectional cohort of pre-treated (>6 months) patients and a subsequent cohort of treatment-naïve patients who were prospectively followed-up. All patients were screened for hypogonadism and received a Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire at study entry and after 6 months of therapy. Patients who were candidates for testosterone replacement therapy (TRT) also received a FACT-G questionnaire at baseline and 3 months after supplementation. RESULTS: Among the 30 enrolled patients, the prevalence of hypogonadism was found to be higher in those receiving sunitinib for a longer period (27.3% at baseline, 41.7% in the first 6 months, and 68.4% after 9 months of therapy). The testosterone level of patients correlated with quality of life (R=0.32). A total of six patients received TRT, with a significant improvement in their global quality of life after the first 3 months of treatment. CONCLUSION: An increasing prevalence of hypogonadism was seen among male patients who received long-term treatment with sunitinib. TRT was associated with relevant improvements in quality of life. These findings corroborate similar published observations and encourage the assessment of gonadal function in male patients with mRCC under treatment with sunitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; alberto.dallavolta@gmail.com.
- Unit of Endocrinology and Metabolism, ASST Spedali Civili, Department of Medicine, University of Brescia, Brescia, Italy.
- Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
- Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
Zitieren
APA
Volta, A. D., Delbarba, A., Valcamonico, F., Cappelli, C., Caramella, I., Bergamini, M., Ferlin, A., & Berruti, A. (2023). Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib. In Vivo. https://doi.org/10.21873/invivo.13093
Vancouver
Volta AD, Delbarba A, Valcamonico F, Cappelli C, Caramella I, Bergamini M, et al. Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib. In Vivo. 2023. doi:10.21873/invivo.13093
BibTeX
@article{Volta2023,
author = {Volta, Alberto Dalla and Delbarba, Andrea and Valcamonico, Francesca and Cappelli, Carlo and Caramella, Irene and Bergamini, Marco and Ferlin, Alberto and Berruti, Alfredo},
title = {Gonadal Function in Male Patients With Metastatic Renal Cell Cancer Treated With Sunitinib},
journal = {In Vivo},
year = {2023},
doi = {10.21873/invivo.13093}
}
EUVIMED